Journament

Keyword Connections - clostridium difficile infection Keywords

Connection Type	Connection
Journals	world journal of emergency surgery : wjes journal of medical economics
Research Groups	No Research Group Connected
Bibliographies	[1] Healthcare resource utilization and direct medical costs associated with index and recurrent infection: A real-world data analysis. [2] 2019 update of the WSES guidelines for management of () infection in surgical patients. [3] Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial [4] antimicrobial use, human gut microbiota and clostridium difficile colonization and infection [5] applying fecal microbiota transplantation (fmt) to treat recurrent clostridium difficile infections (rcdi) in children [6] Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis [7] Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value [8] Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm [9] Community-acquired Clostridium difficile infection: an increasing public health threat [10] Emerging therapies for Clostridium difficile infection – focus on fidaxomicin [11] Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis [12] Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value [13] Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm [14] Community-acquired Clostridium difficile infection: an increasing public health threat [15] Emerging therapies for Clostridium difficile infection – focus on fidaxomicin [16] Implementation of a Checklist to Reduce False-Positive Testing in Hospital-Acquired Clostridium Difficile Infection. [17] Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance [18] Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection [19] Clostridium difficile infection in fever patients with gynecological malignancies [20] Staggered and Tapered Antibiotic Withdrawal With Administration of Kefir for Recurrent Clostridium difficile Infection [21] Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection [22] Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship [23] Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials [24] Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections [25] A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+) [26] Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study [27] Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections [28] Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial [29] Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection [30] Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection [31] Patient Attitudes Toward the Use of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile Infection [32] Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis [33] Pathway to Prevention of Nosocomial Clostridium difficile Infection [34] Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial [35] Prevention of Clostridium difficile Infection With Probiotics [36] Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection [37] Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin [38] Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients [39] Diarrhea and Clostridium difficile Infection in Latin American Patients with AIDS [40] Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection [41] Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection [42] Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015 [43] severe clostridium difficile infections. a systematic literature -review- [44] clostridium difficile infection outbreak in a male rehabilitation ward, hong kong (china), 2011 [45] applying fecal microbiota transplantation (fmt) to treat recurrent clostridium difficile infections (rcdi) in children [46] biofilm structures in a mono-associated mouse model of clostridium difficile infection [47] application of antibody-mediated therapy for treatment and prevention of clostridium difficile infection [48] treating clostridium difficile infections: should fecal microbiota transplantation be reclassified from investigational drug to human tissue? [49] anaerobically cultivated human intestinal microbiota as first-line treatment for clostridium difficile infection [50] refractory clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin [51] reducing the risk of severe complications among patients with clostridium difficile infection [52] prevalence of clostridium difficile infection among the patients attending a tertiary care teaching hospital [53] clostridium difficile infection and proton pump inhibitor use in hospitalized pediatric cystic fibrosis patients [54] emergence of community-acquired clostridium difficile infection: the experience of a french hospital and review of the literature [55] low risk of irritable bowel syndrome after clostridium difficile infection [56] Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) [57] Comparison of clinical severity score indices for Clostridium difficile infection [58] Is primary prevention of Clostridium difficile infection possible with specific probiotics? [59] Predictors of Death after Clostridium difficile Infection: A Report on 128 Strain-Typed Cases from a Teaching Hospital in the United Kingdom [60] Fidaxomicin versus vancomycin for Clostridium difficile infection [61] Health Care-Associated Clostridium difficile Infection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and Mortality [62] Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) [63] The Impact of ICD-9-CM Code Rank Order on the Estimated Prevalence of Clostridium difficile Infections [64] Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection